|
1
|
He J, Gu D, Wu X, et al: Major causes of
death among men and women in China. N Engl J Med. 353:1124–1134.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: from genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kreuger J, Perez L, Giraldez AJ and Cohen
SM: Opposing activities of Dally-like glypican at high and low
levels of Wingless morphogen activity. Dev Cell. 7:503–512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filmus J, Capurro M and Rast J: Glypicans.
Genome Biol. 9:2242008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Capurro MI, Xiang YY, Lobe C and Filmus J:
Glypican-3 promotes the growth of hepatocellular carcinoma by
stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stigliano I, Puricelli L, Filmus J,
Sogayar MC, Bal de Kier Joffe E and Peters MG: Glypican-3 regulates
migration, adhesion and actin cytoskeleton organization in mammary
tumor cells through Wnt signaling modulation. Breast Cancer Res
Treat. 114:251–262. 2009. View Article : Google Scholar
|
|
8
|
Peters MG, Farias E, Colombo L, Filmus J,
Puricelli L and Bal de Kier Joffe E: Inhibition of invasion and
metastasis by glypican-3 in a syngeneic breast cancer model. Breast
Cancer Res Treat. 80:221–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aviel-Ronen S, Lau SK, Pintilie M, et al:
Glypican-3 is overexpressed in lung squamous cell carcinoma, but
not in adenocarcinoma. Mod Pathol. 21:817–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Capurro M, Wanless IR, Sherman M, et al:
Glypican-3: a novel serum and histochemical marker for
hepatocellular carcinoma. Gastroenterology. 125:89–97. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Filmus J and Capurro M: Glypican-3 and
alphafetoprotein as diagnostic tests for hepatocellular carcinoma.
Mol Diagn. 8:207–212. 2004. View Article : Google Scholar
|
|
12
|
Liu H, Li P, Zhai Y, et al: Diagnostic
value of glypican-3 in serum and liver for primary hepatocellular
carcinoma. World J Gastroenterol. 16:4410–4415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li B, Liu H, Shang HW, Li P, Li N and Ding
HG: Diagnostic value of glypican-3 in alpha fetoprotein negative
hepatocellular carcinoma patients. Afr Health Sci. 13:703–709.
2013.PubMed/NCBI
|
|
14
|
Llovet JM, Chen Y, Wurmbach E, et al: A
molecular signature to discriminate dysplastic nodules from early
hepatocellular carcinoma in HCV cirrhosis. Gastroenterology.
131:1758–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang XY, Degos F, Dubois S, et al:
Glypican-3 expression in hepatocellular tumors: diagnostic value
for preneoplastic lesions and hepatocellular carcinomas. Hum
Pathol. 37:1435–1441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miao HL, Pan ZJ, Lei CJ, et al: Knockdown
of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma
cells through down-regulation of YAP. J Cell Biochem. 114:625–631.
2013. View Article : Google Scholar
|
|
17
|
Zittermann SI, Capurro MI, Shi W and
Filmus J: Soluble glypican 3 inhibits the growth of hepatocellular
carcinoma in vitro and in vivo. Int J Cancer. 126:1291–1301.
2010.
|
|
18
|
Bruix J and Sherman M; Practice Guidelines
Committee AAftSoLD. Management of hepatocellular carcinoma.
Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu YL, Wang NN, Gu L, Yang HM, Xia N and
Zhang H: The suppressive effect of metabotropic glutamate receptor
5 (mGlu5) inhibition on hepatocarcinogenesis. Biochimie.
94:2366–2375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vauthey JN, Lauwers GY, Esnaola NF, et al:
Simplified staging for hepatocellular carcinoma. J Clin Oncol.
20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding W, You H, Dang H, et al:
Epithelial-to-mesenchymal transition of murine liver tumor cells
promotes invasion. Hepatology. 52:945–953. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang W, Mendoza MC, Pei X, et al:
Down-regulation of CMTM8 induces epithelial-to-mesenchymal
transition-like changes via c-MET/extracellular signal-regulated
kinase (ERK) signaling. J Biol Chem. 287:11850–11858. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Lingala S, Khoobyari S, Nolta J,
Zern MA and Wu J: Epithelial mesenchymal transition and hedgehog
signaling activation are associated with chemoresistance and
invasion of hepatoma subpopulations. J Hepatol. 55:838–845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun CK, Chua MS, He J and So SK:
Suppression of glypican 3 inhibits growth of hepatocellular
carcinoma cells through up-regulation of TGF-beta2. Neoplasia.
13:735–747. 2011.PubMed/NCBI
|
|
26
|
Cheng W, Tseng CJ, Lin TT, et al:
Glypican-3-mediated oncogenesis involves the Insulin-like growth
factor-signaling pathway. Carcinogenesis. 29:1319–1326. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pan Z, Chen C, Long H, et al:
Overexpression of GPC3 inhibits hepatocellular carcinoma cell
proliferation and invasion through induction of apoptosis. Mol Med
Rep. 7:969–974. 2013.PubMed/NCBI
|
|
28
|
Sung YK, Hwang SY, Farooq M, Kim JC and
Kim MK: Growth promotion of HepG2 hepatoma cells by
antisense-mediated knockdown of glypican-3 is independent of
insulin-like growth factor 2 signaling. Exp Mol Med. 35:257–262.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin CW, Mars WM, Paranjpe S, et al:
Hepatocyte proliferation and hepatomegaly induced by phenobarbital
and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in
hepatocyte-targeted glypican 3 transgenic mice. Hepatology.
54:620–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
the importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu M, Yin F, Fan X, et al: Decreased
TIP30 promotes Snail-mediated epithelial-mesenchymal transition and
tumor-initiating properties in hepatocellular carcinoma. Oncogene.
Mar 31–2014.(Epub ahead of print). View Article : Google Scholar
|
|
33
|
Cho NH, Shim HS, Rha SY, et al: Increased
expression of matrix metalloproteinase 9 correlates with poor
prognostic variables in renal cell carcinoma. Eur Urol. 44:560–566.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li H, Wang H, Wang F, Gu Q and Xu X: Snail
involves in the transforming growth factor beta1-mediated
epithelial-mesenchymal transition of retinal pigment epithelial
cells. PLoS One. 6:e233222011. View Article : Google Scholar
|
|
35
|
Suh Y, Yoon CH, Kim RK, et al: Claudin-1
induces epithelial-mesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar
|
|
36
|
Huang XY, Ke AW, Shi GM, et al:
alphaB-crystallin complexes with 14-3-3zeta to induce
epithelial-mesenchymal transition and resistance to sorafenib in
hepatocellular carcinoma. Hepatology. 57:2235–2247. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoshida S, Kornek M, Ikenaga N, et al:
Sublethal heat treatment promotes epithelial-mesenchymal transition
and enhances the malignant potential of hepatocellular carcinoma.
Hepatology. 58:1667–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
